Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset
Chandler M, Recht M, He C, Moulton T, Charafi L. Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset. Blood 2021, 138: 4241. DOI: 10.1182/blood-2021-152345.Peer-Reviewed Original ResearchDamoctocog alfa pegolHemophilia treatment centersAdolescent patientsBleeding rateTreated twice-weeklyHistory of inhibitorsYear of therapyAmerican ThrombosisAge of patientsMonths of treatmentSevere hemophilia ASubgroup of patientsHemophilia A patientsProportion of patientsBaseline demographic dataPatient chart reviewReal-world studyHemostasis NetworkData cutoffA patientsBleeding eventsWeekly dosesHemophilia AChart reviewOregon Health & Science UniversityEffectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 2213-2225. PMID: 33491157, PMCID: PMC8107067, DOI: 10.1007/s12325-020-01613-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerMetastatic breast cancerObjective response rateProgression-free survivalMedian progression-free survivalMedian overall survivalOverall survivalBreast cancerClinical practiceRetrospective chart review studyReal-world clinical experienceReal-world clinical practiceUS indicationEffectiveness of eribulinThird-line therapyPatient chart reviewChart review studyReal-world effectivenessNegative breast cancerElectronic case report formCase report formsEligible patientsMetastatic settingChart reviewTreatment landscape
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply